| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 434.2 | 402.8 | 318.5 |
| Other income | 1.7 | 1.8 | 1.9 |
| Total income | 435.9 | 404.6 | 320.4 |
| Profit before exceptional items & tax | -8.5 | -18.8 | -47.0 |
| Exceptional items | 0.0 | 8.9 | 0.0 |
| Profit before tax | -8.5 | -9.9 | -47.0 |
| Net profit | -6.1 | -7.4 | -34.9 |
| Operating margin | -1.9% | -2.4% | -14.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Revenue, year on year | +36.30% |
|---|---|
| Operating profit, year on year | +79.10% |
| Operating profit, quarter on quarter | +50.50% |
BSE results filing, NSE: HIKAL. Figures extracted from the filing.
Hikal Ltd: key numbers
- Share price
- ₹214.53
- Market cap
- ₹2,645 Cr
- Revenue (annual)
- ₹1,713 Cr
- Net profit (annual)
- ₹-48.80 Cr
- P/E (TTM)
- -529.0×Sector 47.2×
- Promoter holding
- 68.85%+0.00% QoQ
- FII holding
- 1.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hikal Ltd
All →Hikal Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹434 Cr (+36% YoY), EBITDA ₹45 Cr at 10.3% margin, PAT loss narrowed to ₹(6) Cr. Pharma led recovery; Crop Protection margins pressured.
Hikal Results Update
Hikal Ltd reported Q2 FY27 revenue of ₹434 Crore and an EBITDA of ₹45 Crore. The company also announced the commencement of commercial production for Personal Care at its Panoli facility.
- Value
- ₹434.0 Cr
Hikal Bags New Order from Europe-based global agrochemical company
Hikal signed a multi-year CDMO contract with a Europe-based global agrochemical company for a specialised product. Commercial launch is expected towards the end of FY 2026-27.
- From
- Europe-based global agrochemical company (unnamed)
- Execution
- Multi-year
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Hikal Other Announcement
Hikal Ltd filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing reports routine ownership data with no new transaction.
Hikal Board Meeting Date
Hikal's board meets November 3, 2026 to consider September quarter and half-year results. The results are yet to be approved.